s of magnitude greater than the TFV IVRs. Targeting molecular transporters in the VT for enhanced bioavailability may provide a powerful strategy in the rational design and selection of ARV prodrugs in topical HIV PrECP. Existing antiviral prodrugs that benefit from carriermediated transport to increase their oral bioavailability include the commercially available L-valyl ester of acyclovir and mono- and di-peptide prodrugs of acyclovir, ganciclovir, and saquinavir developed by Mitra and colleagues. All these prodrugs target PEPT1 and, to a lesser extent, PEPT2, membrane transporters that were under-expressed in all samples measured here. Our findings suggest that the peptidic prodrugs may not significantly enhance the bioavailability of the parent compound if administered intravaginally, although additional research is required to more thoroughly characterize these interactions. Given the 12 Molecular Transporters in 26574517 the Human Vaginal Tract successful evaluation reported in this global analysis of the VT transcriptome, the most highly expressed of molecular transporters present in the VT can now be better targeted with refined drug design. Dataset S1. Microarray membrane transporter gene expression dataset. The introduction of combination anti-retroviral therapy in 1996 transformed the epidemiology of HIV infection and prolonged survival of infected individuals in the United States. MedChemExpress Chebulinic acid However, during this interval, the 
incidence of nonAIDS-defining malignancies has increased. Hodgkin lymphoma is one of the most commonlydiagnosed NADMs among HIV-infected persons. Previous studies have demonstrated that HL risk is over 10-fold higher among HIV-infected individuals than the general population , and have also shown HL incidence to be increasing in the cART era. Although HIV-related HL has been strongly linked to the Epstein-Barr virus, the causes for the increased HL incidence in the cART era remain unclear. Previous studies have described the complex influence of immune function in mediating HL development in this population; however, these studies have been limited by relatively small samples, and findings have been largely inconsistent. Furthermore, there is limited research examining HIV-related immune factors and immune reconstitution 1 HIV-Related Hodgkin Lymphoma Incidence associated with increased HL incidence in a cohort of individuals receiving cART. The aim of the present study was to evaluate the effect of immune reconstitution on HL incidence among a cohort of male US military veterans ever 18201139 receiving cART and diagnosed with HIV infection between 1985 and 2010. diagnosis date) were excluded. The follow-up interval for longitudinal analyses spanned from the index visit to HL diagnosis, death or December 31, 2010, whichever occurred first. Data management and definitions To account for potential differences in the frequency of follow-up visits for registry patients, each individual’s follow-up duration was divided into 7-day intervals. Laboratory values were updated at the beginning of each interval, with the last observation carried forward when no new measurement was available. Immune function prior to cART was estimated from the nadir CD4 count over the interval from HIV diagnosis to cART initiation. For individuals who received cART on the same date as the HIV diagnosis, the initial CD4 count was captured as the nadir. Time-updated recent CD4 count was included to monitor the effect of fluctuations in immune status throughout
